查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363049

遺傳性血管水腫治療藥物市場規模、佔有率和趨勢分析報告：2023-2030 年按治療、給藥途徑、最終用途、地區和細分市場分類的趨勢

Hereditary Angioedema Therapeutics Market Size, Share & Trends Analysis Report By Treatment (Bradykinin B2 Receptor Antagonist, C1-Esterase Inhibitor), By Route of Administration, By End Use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

遺傳性血管水腫治療藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球遺傳性血管水腫治療市場規模將達58億美元，2023年至2030年年複合成長率為7.4%。

國際患者組織為提高患者和醫療保健提供者對遺傳性血管性水腫 (HAE) 的認知而採取的舉措可能會成為市場的有力促進因素。

隸屬於 HAE International (HAEi) 的病患權益團體致力於透過印刷品和社群媒體進行宣傳活動，以提高人們對遺傳性血管性水腫的認知。 HAEi 也推出了居家檢測工具來提高患者的意識層級，這將有助於提供準確的診斷和最佳的醫療照護。 CSL Limited、Pharming Group NV 和 Shire Plc. 等製藥和生物技術公司也參與開發 HAE治療方法，並與遺傳性血管水腫界合作，致力於建立有效的遺傳性血管水腫診斷流程和治療方法。

世界不同國家的大學正在相互合作開發新的治療方法來控制遺傳性血管水腫的發作。例如，2018 年，來自歐洲、澳洲和加拿大的 26 所大學開展了一項國際合作，開發預防這種疾病的新型口腔療法。

各國正在採取措施改善患者獲得新治療方法的機會，並修訂法規指南以促進 HAE 藥物的快速審查和核准，預計將有助於市場成長。例如，2018年7月，中國國家衛生健康委員會（NHC）和國家藥品監督（SDA）宣布，藥品生產商可以申請新藥認證，用於治療方法目前國內尚無治療方法的罕見疾病。（保密協議）。該決定允許藥品生產企業在申請新藥認證時使用中國境外的臨床試驗資料。

遺傳性血管水腫治療藥物市場報告亮點

  • 由於產品在 HAE 的按需和預防性治療中的高利用率，C1 酯酶抑制劑細分市場在 2022 年佔據最大佔有率。
  • 按需治療佔據了市場的壓倒性佔有率，預計在預測期內將出現良好的成長。新地區的產品推出預計將成為該細分市場的主要促進因素。
  • 以 2022 年銷售額計算，北美在整個遺傳性血管水腫治療藥物市場中佔據主導地位。這種疾病病例數量的增加、有利的政府計劃、患者意識水平的提高以及高度專業化的醫療保健專業人員的存在是促成該區域市場主要佔有率的要素。
  • 由於醫療基礎設施的改善和未滿足的醫療需求較高，預計亞太地區在預測期內將出現良好的成長。此外，治療這種疾病的新治療方法的推出可能會推動該地區的市場成長。
  • 主要參與者包括 Ionis Pharmaceuticals, Inc.、BioCryst Pharmaceuticals, Inc.、Pharming Group NV、CSL Limited、Shire plc、Adverum Biotechnologies, Inc.、Attune Pharmaceuticals, Inc.、KalVista Pharmaceuticals, Inc.。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 遺傳性血管水腫治療藥物市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 遺傳性血管水腫治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 遺傳性血管水腫治療藥物市場：依治療方法估計與趨勢分析

  • 遺傳性血管水腫治療市場：重點
  • 遺傳性血管水腫治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • C1-酯酶抑制劑
  • 緩激肽 B2 受體拮抗
  • 激肽釋放酶抑制劑
  • 其他

第5章 遺傳性血管水腫治療藥物市場：依最終用途的估計與趨勢分析

  • 遺傳性血管水腫治療市場：重點
  • 遺傳性血管水腫治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 預防
  • 按需

第6章 遺傳性血管水腫治療藥物市場：依給藥途徑估計與趨勢分析

  • 遺傳性血管水腫治療市場：重點
  • 遺傳性血管水腫治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 靜脈
  • 皮下的
  • 口服

第7章 遺傳性血管水腫治療藥物市場：區域估計與趨勢分析

  • 區域展望
  • 按地區分類的遺傳性血管水腫治療藥物市場：重點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • BioCryst Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals
    • CSL
    • Attune Pharmaceuticals
    • Adverum Biotechnologies, Inc.
    • KalVista Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Pharming
Product Code: GVR-3-68038-156-6

Hereditary Angioedema Therapeutics Market Growth & Trends:

The global hereditary angioedema therapeutic market size is expected to reach USD 5.8 billion by 2030, according to a new report by Grand View Research, Inc.., exhibiting a 7.4% CAGR from 2023 to 2030. Growing initiatives by international patient organizations to improve awareness about hereditary angioedema (HAE) among patients and healthcare providers is likely to be a high impact rendering driver for the market.

Patient advocacy organizations affiliated to HAE International (HAEi) are focusing on campaigns through both print and social media in order to raise awareness levels for hereditary angioedema. HAEi has also introduced family testing tools for improving patient awareness levels, which is likely to help in providing accurate diagnosis and optimal medical treatment. Pharmaceutical and biotechnology companies such as CSL Limited, Pharming Group N.V., and Shire Plc. engaged in development of therapies for HAE have also lent their support and collaborated with the hereditary angioedema community so as to create effective diagnosis process and treatment for the condition.

Universities in different countries across the globe are collaborating with each other in order to develop new therapies for the management of hereditary angioedema attacks. For instance, in 2018, 26 universities from Europe, Australia, and Canada collaborated on an international study to develop a novel oral therapy for prevention of the condition.

Measures undertaken by countries for improving patient access to new therapies, along with modification in regulatory guidelines for facilitating faster drug review and approval for HAE, are expected to contribute to market growth. For instance, in July 2018, China's National Health Commission (NHC) and State Drug Administration (SDA) allowed pharmaceutical drug manufacturers to file for New Drug Application (NDA) for therapies for rare diseases whose treatment is currently not available in the country. The decision has allowed drug manufacturers to use clinical trial data from outside China while filing for NDA.

Hereditary Angioedema Therapeutics Market Report Highlights:

  • The C1-esterase inhibitor segment held the largest share in 2022 owing to high usage rates of the products in on-demand and prophylactic treatment of HAE
  • On-demand treatment accounted for the dominant share in the market and is expected to witness lucrative growth over the forecast period. Expected launch of products in new geographies is likely to be a key growth driver for the segment
  • North America dominated the overall hereditary angioedema therapeutics market in terms of revenue in 2022. Growing number of cases of the condition, favorable government programs, increasing awareness levels among patients, and presence of highly expert healthcare professionals are factors contributing to the major share of this regional market
  • Asia Pacific is expected to register lucrative growth over the forecast period owing to improving healthcare infrastructure and high unmet medical needs. Moreover, launch of new therapies for the treatment of the condition is likely to facilitate market growth in the region
  • Key players include Ionis Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Pharming Group N.V.; CSL Limited; Shire plc; Adverum Biotechnologies, Inc.; Attune Pharmaceuticals, Inc.; and KalVista Pharmaceuticals, Inc.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. End-use
    • 1.1.3. Route of administration
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. End-use outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hereditary Angioedema Therapeutic Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Hereditary Angioedema Therapeutic Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Hereditary Angioedema Therapeutic Market: Treatment Estimates & Trend Analysis

  • 4.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 4.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. C1-esterase Inhibitor
    • 4.3.1. C1-esterase inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.4. Bradykinin B2 Receptor Antagonist
    • 4.4.1. Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.5. Kallikrein Inhibitor
    • 4.5.1. Kallikrein inhibitor market estimates and forecasts, 2018 to 2030, (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Hereditary Angioedema Therapeutic Market: End-use Estimates & Trend Analysis

  • 5.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 5.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Prophylaxis
    • 5.3.1. Silicon market estimates and forecasts, 2018 to 2030, (USD Million)
  • 5.4. On-demand
    • 5.4.1. Metal market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Hereditary Angioedema Therapeutic Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Hereditary Angioedema Therapeutic Market: Key Takeaways
  • 6.2. Hereditary Angioedema Therapeutic Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Intravenous
    • 6.3.1. Intravenous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.4. Subcutaneous
    • 6.4.1. Subcutaneous market estimates and forecasts, 2018 to 2030, (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 7. Hereditary Angioedema Therapeutic Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Hereditary Angioedema Therapeutic Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. Saudi Arabia
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. BioCryst Pharmaceuticals, Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Ionis Pharmaceuticals
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. CSL
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Attune Pharmaceuticals
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Adverum Biotechnologies, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. KalVista Pharmaceuticals, Inc.
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Takeda Pharmaceutical Company Limited
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Pharming
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiative

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 North America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 4 North America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 U.S. hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Canada hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Canada hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 Europe hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Europe hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Germany hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 18 Germany hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 UK hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 UK hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 21 UK hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 France hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 24 France hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 Italy hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 Italy hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 27 Italy hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Spain hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Spain hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 30 Spain hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
  • Table 31 Denmark hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Denmark hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 33 Denmark hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Sweden hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 Sweden hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 36 Sweden hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Norway hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Norway hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 39 Norway hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 Japan hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 46 Japan hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 - 2030
  • Table 47 China hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 China hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 49 China hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 India hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 India hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 52 India hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
  • Table 53 Australia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 Australia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 55 Australia hereditary angioedema therapeutics market, by route of administration, (USD Million) 2018 -2030
  • Table 56 Thailand hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 Thailand hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 58 Thailand hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 South Korea hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Korea hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 61 South Korea hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Latin America hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 Latin America hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 64 Latin America hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Latin America hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Brazil hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Brazil hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 Mexico hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 Mexico hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 Mexico hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 Argentina hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 Argentina hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa hereditary angioedema therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 81 South Africa hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 UAE hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 87 UAE hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Kuwait hereditary angioedema therapeutics market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait hereditary angioedema therapeutics market, by end-use, 2018 - 2030 (USD Million)
  • Table 90 Kuwait hereditary angioedema therapeutics market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hereditary angioedema therapeutics: Market outlook
  • Fig. 9 Hereditary angioedema therapeutics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Hereditary angioedema therapeutics market driver impact
  • Fig. 15 Hereditary angioedema therapeutics market restraint impact
  • Fig. 16 Hereditary angioedema therapeutics market strategic initiatives analysis
  • Fig. 17 Hereditary angioedema therapeutics market: Treatment movement analysis
  • Fig. 18 Hereditary angioedema therapeutics market: Treatment outlook and key takeaways
  • Fig. 19 C1-esterase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Bradykinin B2 receptor antagonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Kallikrein inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Hereditary angioedema therapeutics market: End-use movement analysis
  • Fig. 24 Hereditary angioedema therapeutics market: End-use outlook and key takeaways
  • Fig. 25 Prophylaxis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 On-demand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Hereditary angioedema therapeutics market: Route of administration movement analysis
  • Fig. 28 Hereditary angioedema therapeutics market: Route of administration outlook and key takeaways
  • Fig. 29 Intravenous market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Subcutaneous market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Global hereditary angioedema therapeutics market: Regional movement analysis
  • Fig. 33 Global hereditary angioedema therapeutics market: Regional outlook and key takeaways
  • Fig. 34 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)